Back to Results
First PageMeta Content
Experimental cancer treatments / Vaccination / Oncology / Dendreon / Cancer immunotherapy / Immunotherapy / Tumor antigen / Biovest / TroVax / Medicine / Immunology / Cancer vaccines


Document Date: 2010-08-13 15:57:08

Open Document

File Size: 1,76 MB

Share Result on Facebook

City

San Francisco / Houston / Osaka / Bern / Austin / Toronto / Milan / Doylestown / Durham / St. Louis / Seattle / Boston / Sydney / Cambridge / Los Angeles / Fremont / Tampa / Brussels / Paris / Philadelphia / Munich / Ankara / New York City / Worcester / New York / London / Darmstadt / San Diego / /

Company

Avax Technologies / Merck KGaA / Genentech / Accentia Biopharma / GlaxoSmithKline Biologicals / Nature America Inc. / CancerVax / Oncothyreon Merck KgaA / Pfizer / Celldex Therapeutics / Biovest International / Oxford Biomedica / Rodman and Renshaw / Atlas Ventures / Box 2 Pharma / Dendreon / Coley Pharmaceutical Group / Edmunton AB / Antigenics / Biovest B / Micromet / IDM Pharma / Geron / Needham / Glaxosmithkline plc / /

Continent

Europe / /

Country

Denmark / Switzerland / Canada / Australia / Germany / Belgium / Russia / United States / /

Currency

USD / /

Event

FDA Phase / Business Partnership / M&A / Bankruptcy / /

Facility

C terminus / H. Lee Moffitt Cancer Center / Stanford University laboratory of Ron Levy / University of Connecticut’s Center / University of Miami / Duke University / N terminus / University School / MD Anderson Hospital / National Cancer Institute / /

IndustryTerm

biotechnology volume / pharmaceutical industry / majority-owned subsidiary / cancer therapy / sustained bodywide search / biotechnology / pharmaceutical giant / invariant chain / biotechnology feature / manufacturing / manufactured product / tumor vaccine products / technology-intensive vaccines / oil droplet emulsion containing monophosphoryl lipid / /

MedicalCondition

several potential tumor / glioblastoma cells / myelodysplastic syndrome / whole-cellbased active cancer / B-cell lymphoma produce antibodies / therapeutic cancer / bladder cancer / amyotrophic lateral sclerosis / Beginnings Cancer / Biovest B-cell lymphoma / microscopic disease / non-small-cell lung cancer / renal cancer / complete tumor / glioblastoma / antigens Cancer / rapidly dividing cancer / residual tumor / tumor / patient’s tumor / Pevi-Pro Influenza / cervical cancer / glioblastomas / lymphomas / Melanoma cancer vaccine Melanoma / antigen melanoma NSCLC / T cells Tumor / polio / lymphoma division / sarcoma / human papilloma virus / different active cancer / stage cancer / particular cancer / stable disease / previously occult tumor / common cancers / Cellular cancer / glioblastoma multiforma requiring surgery / non-Hodgkin’s lymphomas / seemingly excised tumor / latestage disease / lymphoma / advanced pancreatic cancer / patient tumor / cell-based allogeneic tumor / skin rash / renal cell funding carcinoma / excised tumors / few cancers / One allogeneic leukemia / late-stage disease / resected tumor / breast cancers / disease / vaccinia strain Ankara / Ii-Key/HER2/neu cancer / EGFRvIII-positive glioblastomas / M1b stage disease / certain tumor / autoimmune colitis / advanced cancer / lung cancer / Further complicating cancer / brain cancer / unique tumor / sufficient tumor / Recurrent glioma / multiple myeloma / residual disease / III melanoma / smallpox / NSCLC tumors / renal-cell carcinoma / individual patient’s excised tumor / autologous tumor / melanoma / SCLC / earlystage disease / Liposomally packaged cancer Metastatic MAGE-A3 / least one tumor / hepatitis / feature Tumor / prostate cancer / Breast cancer / resected tumor Collidem Melanoma / either tumor / both tumor / advanced cancers / cancer / earlier-stage disease / Tumors / NSCLC / melanomas / chronic myelogenous leukemia / active cancer / visible tumor / metastases / hormone-resistant / prostate cancer / Metastatic melanoma / advanced disease / carcinoma / scale-up headaches / metastatic breast cancer / enough patients’ tumors / irradiated melanoma / infectious agents / glioblastoma makes / cancers / numerous tumor / vaccine containing cancer / minimal residual disease / lung tumors / GVAX pancreatic Two allogeneic cultured cancer / dendritic cell precusor Tumor / hormonerefractory prostate cancer / perilous path Cancer / kidney tumors / cell Cancer / lymphoma cells / Selected cancer / prostate tumors / bacterial incision-wound infection / autoimmune prostatitis / Superficial bladder cancer / /

MedicalTreatment

incision / surgery / chemotherapy / surgeries / vaccinations / vaccination / Immunotherapy / radiation / cancer therapy / immunosuppression / passive immunotherapies / immunization / immunotherapies / Active immunotherapies / /

Organization

Washington University School of Medicine / American Society of Clinical Oncology Conference in Orlando / National Cancer Institute / Johns Hopkins University / University of Miami / University of Connecticut’s Center for Immmunotherapy of Cancer and Infectious Diseases / independent review committee / Center for Biologicals Evaluation and Research / Duke University / American Society of Clinical Oncology in Chicago / H. Lee Moffitt Cancer Center / Comprehensive Melanoma Research Center / European Medicines Agency / US Food and Drug Administration / Stanford University / Center for the Study / /

Person

Amy Heimberger / Robert Schreiber / Pramod Srivastava / Chelsea Heights / John Sampson / Cell Genesys Takeda (Osaka) / All / Vincent Brichard / Larry Kwak / Mark Frohlich / Garo Armen / Chuck Baum / Thomas Okarma / Christopher Wood / Angelos Stergiou / Peter Bross / Laura DeFrancesco / William Coley / Bruce Booth / Jeffrey Weber / Reni Benjamin / Eli Gilboa / Bruce Goldman / Marita Hobman / /

Position

physician / member of the board / chief / freelance writer / CEO / knowledgeable company official / senior biotech analyst / senior vice-president and head of the oncology development / Editor / cancer researcher / chief medical officer / chief medical officer and head of clinical research / senior vice-president for cancer immunotherapeutics / senior vice president of clinical affairs and chief medical officer / principal investigator and author / head / company co-founder / director of intellectual property / director / forward / /

Product

Herceptin / Rituxan / BiovaxID injections / 40 0 immunoprotective / prophylatic vaccine / Provenge / ICT-107 / Peptide vaccine / HSPPC-96 / Russia / RAD50 / 3 Autologous cell vaccine / Immunogenic peptide / IMT-1012 / Vx-001 / MAGE-3 / AGS-033 / M1b / United States / M1a / MUC-1 / AGS-003 / M3TK / Oncothyreon Stimuvax Liposomal vaccine / GV1001 / /

ProgrammingLanguage

FL / /

ProvinceOrState

Connecticut / Florida / /

PublishedMedium

The Lancet / Nature Biotechnology / /

SportsLeague

Stanford University / /

Technology

radiation / proteomics / chemotherapy / treating cancer / immunotherapeutics / antibodies / Biotechnology / immune stimulants / trial protocols / stem cells / Drug Development / /

URL

http /

SocialTag